Are kidney transplant recipients on belatacept developing operational tolerance?

Are kidney transplant recipients on Belatacept developing operational tolerance?

Principal Investigator: Dr. Minnie Sarwal.

Drs. Minnie Sarwal, Matthew Vitalone, Tara SigdelThe Sarwal Lab
Stanford University Medical School
300 Pasteur Drive, S-378 Grant Building
Stanford, CA 94305

Drs. Luis Llorente, Janette Furuzawa, Guadalupe Lima, Ian Bostock, LuisE. Morales Buenrostro, Josefina Alberú
Department of Immunology and Department of Transplantation. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Vasco de Quiroga15, Delegación Tlalpan, CP 14000. Mexico City.
Dr. Eduardo Mancilla (PI for IM103008 at Instituto Nacional de Cardiologia ICh, Mexico City)
Dr. Rafael Reyes-Acevedo (PI for IM103008at Hospital Miguel Hidalgo, Aguascalientes, México)
Dr. Guillermo Mondragón (PI for IM103008 Instituto Nacional de Trasplantes, Morelos, México)
Dr. Alejandro Chevaile (PI forIM103008 Hospital Ignacio Morones Prieto, San Luis Potosí, México)

Please note that we can start the study in January 2012. The cross-sectional design of this study will require onevisit/per patient only to conduct it.
o   Planned FPFV: 15 January 2012
o   Planned LPFV: 15 June 2012
* Patients: 70 pts
* Control group: ~ 30 healthy kidney donors
*Sites: 5
Please note that the patients to be invited and included are those “on treatment” participating in the IM103008 study.

The treatment of choice for end stage organ deficienciesis organ transplantation. A disadvantage is that the maintenance regimens for these organs require the use of long term immunosuppressive therapies. The increased incidence ofinfections, malignancies and other side effects are known complications of these drugs. It has also been established that immunosuppression has a negative influence on chronic rejection and long